Literature DB >> 21248032

Prion propagation in cells expressing PrP glycosylation mutants.

Muhammad K Salamat1, Michel Dron, Jérôme Chapuis, Christelle Langevin, Hubert Laude.   

Abstract

Infection by prions involves conversion of a host-encoded cell surface protein (PrP(C)) to a disease-related isoform (PrP(Sc)). PrP(C) carries two glycosylation sites variably occupied by complex N-glycans, which have been suggested by previous studies to influence the susceptibility to these diseases and to determine characteristics of prion strains. We used the Rov cell system, which is susceptible to sheep prions, to generate a series of PrP(C) glycosylation mutants with mutations at one or both attachment sites. We examined their subcellular trafficking and ability to convert into PrP(Sc) and to sustain stable prion propagation in the absence of wild-type PrP. The susceptibility to infection of mutants monoglycosylated at either site differed dramatically depending on the amino acid substitution. Aglycosylated double mutants showed overaccumulation in the Golgi compartment and failed to be infected. Introduction of an ectopic glycosylation site near the N terminus fully restored cell surface expression of PrP but not convertibility into PrP(Sc), while PrP(C) with three glycosylation sites conferred cell permissiveness to infection similarly to the wild type. In contrast, predominantly aglycosylated molecules with nonmutated N-glycosylation sequons, produced in cells expressing glycosylphosphatidylinositol-anchorless PrP(C), were able to form infectious PrP(Sc). Together our findings suggest that glycosylation is important for efficient trafficking of anchored PrP to the cell surface and sustained prion propagation. However, properly trafficked glycosylation mutants were not necessarily prone to conversion, thus making it difficult in such studies to discern whether the amino acid changes or glycan chain removal most influences the permissiveness to prion infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248032      PMCID: PMC3067877          DOI: 10.1128/JVI.02257-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Fibril conformation as the basis of species- and strain-dependent seeding specificity of mammalian prion amyloids.

Authors:  Eric M Jones; Witold K Surewicz
Journal:  Cell       Date:  2005-04-08       Impact factor: 41.582

2.  Transmissible spongiform encephalopathy strain, PrP genotype and brain region all affect the degree of glycosylation of PrPSc.

Authors:  Robert A Somerville; Scott Hamilton; Karen Fernie
Journal:  J Gen Virol       Date:  2005-01       Impact factor: 3.891

3.  Characterization of the F198S prion protein mutation: enhanced glycosylation and defective refolding.

Authors:  Syed I A Zaidi; Sandra L Richardson; Sabina Capellari; Li Song; Mark A Smith; Bernardino Ghetti; Man-Sun Sy; Pierluigi Gambetti; Robert B Petersen
Journal:  J Alzheimers Dis       Date:  2005-04       Impact factor: 4.472

4.  Loss of glycosylation associated with the T183A mutation in human prion disease.

Authors:  E Grasbon-Frodl; Holger Lorenz; U Mann; R M Nitsch; Otto Windl; H A Kretzschmar
Journal:  Acta Neuropathol       Date:  2004-10-26       Impact factor: 17.088

5.  Blockade of glycosylation promotes acquisition of scrapie-like properties by the prion protein in cultured cells.

Authors:  S Lehmann; D A Harris
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

6.  Selective neuronal targeting in prion disease.

Authors:  S J DeArmond; H Sánchez; F Yehiely; Y Qiu; A Ninchak-Casey; V Daggett; A P Camerino; J Cayetano; M Rogers; D Groth; M Torchia; P Tremblay; M R Scott; F E Cohen; S B Prusiner
Journal:  Neuron       Date:  1997-12       Impact factor: 17.173

7.  Glycosylation deficiency at either one of the two glycan attachment sites of cellular prion protein preserves susceptibility to bovine spongiform encephalopathy and scrapie infections.

Authors:  Erdmute Neuendorf; Artur Weber; Armin Saalmueller; Hermann Schatzl; Kurt Reifenberg; Eberhardt Pfaff; Martin Hermann Groschup
Journal:  J Biol Chem       Date:  2004-09-23       Impact factor: 5.157

8.  Intracellular accumulation of the cellular prion protein after mutagenesis of its Asn-linked glycosylation sites.

Authors:  M Rogers; A Taraboulos; M Scott; D Groth; S B Prusiner
Journal:  Glycobiology       Date:  1990-09       Impact factor: 4.313

9.  Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells.

Authors:  S A Priola; B Caughey; R E Race; B Chesebro
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

Review 10.  Prions.

Authors:  S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

View more
  18 in total

Review 1.  N-glycoprotein macroheterogeneity: biological implications and proteomic characterization.

Authors:  Lucia F Zacchi; Benjamin L Schulz
Journal:  Glycoconj J       Date:  2015-12-05       Impact factor: 2.916

2.  Prion protein glycans reduce intracerebral fibril formation and spongiosis in prion disease.

Authors:  Alejandro M Sevillano; Patricia Aguilar-Calvo; Timothy D Kurt; Jessica A Lawrence; Katrin Soldau; Thu H Nam; Taylor Schumann; Donald P Pizzo; Sofie Nyström; Biswa Choudhury; Hermann Altmeppen; Jeffrey D Esko; Markus Glatzel; K Peter R Nilsson; Christina J Sigurdson
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

3.  A seven-residue deletion in PrP leads to generation of a spontaneous prion formed from C-terminal C1 fragment of PrP.

Authors:  Carola Munoz-Montesino; Djabir Larkem; Clément Barbereau; Angélique Igel-Egalon; Sandrine Truchet; Eric Jacquet; Naïma Nhiri; Mohammed Moudjou; Christina Sizun; Human Rezaei; Vincent Béringue; Michel Dron
Journal:  J Biol Chem       Date:  2020-08-11       Impact factor: 5.157

Review 4.  Mammalian prions: tolerance to sequence changes-how far?

Authors:  Muhammad Khalid Salamat; Carola Munoz-Montesino; Mohammed Moudjou; Human Rezaei; Hubert Laude; Vincent Béringue; Michel Dron
Journal:  Prion       Date:  2012-12-11       Impact factor: 3.931

5.  Generating Bona Fide Mammalian Prions with Internal Deletions.

Authors:  Carola Munoz-Montesino; Christina Sizun; Mohammed Moudjou; Laetitia Herzog; Fabienne Reine; Jérôme Chapuis; Danica Ciric; Angelique Igel-Egalon; Hubert Laude; Vincent Béringue; Human Rezaei; Michel Dron
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

6.  Integrity of helix 2-helix 3 domain of the PrP protein is not mandatory for prion replication.

Authors:  Khalid Salamat; Mohammed Moudjou; Jérôme Chapuis; Laetitia Herzog; Emilie Jaumain; Vincent Béringue; Human Rezaei; Annalisa Pastore; Hubert Laude; Michel Dron
Journal:  J Biol Chem       Date:  2012-04-16       Impact factor: 5.157

7.  Further Characterization of Glycoform-Selective Prions of Variably Protease-Sensitive Prionopathy.

Authors:  Weiguanliu Zhang; Xiangzhu Xiao; Mingxuan Ding; Jue Yuan; Aaron Foutz; Mohammed Moudjou; Tetsuyuki Kitamoto; Jan P M Langeveld; Li Cui; Wen-Quan Zou
Journal:  Pathogens       Date:  2021-04-23

Review 8.  Cell biology of prion strains in vivo and in vitro.

Authors:  Daniel Shoup; Suzette A Priola
Journal:  Cell Tissue Res       Date:  2022-02-02       Impact factor: 5.249

9.  Propagation of RML prions in mice expressing PrP devoid of GPI anchor leads to formation of a novel, stable prion strain.

Authors:  Sukhvir Paul Mahal; Joseph Jablonski; Irena Suponitsky-Kroyter; Anja Maria Oelschlegel; Maria Eugenia Herva; Michael Oldstone; Charles Weissmann
Journal:  PLoS Pathog       Date:  2012-06-07       Impact factor: 6.823

10.  Glycoform-selective prion formation in sporadic and familial forms of prion disease.

Authors:  Xiangzhu Xiao; Jue Yuan; Stéphane Haïk; Ignazio Cali; Yian Zhan; Mohammed Moudjou; Baiya Li; Jean-Louis Laplanche; Hubert Laude; Jan Langeveld; Pierluigi Gambetti; Tetsuyuki Kitamoto; Qingzhong Kong; Jean-Philippe Brandel; Brian A Cobb; Robert B Petersen; Wen-Quan Zou
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.